drugset / Trial / NCT03856697
Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation
Phase 3
Unknown
406 enrolled
Hangzhou ACEA Pharmaceutical Research Co., Ltd.
Guangdong Provincial People's Hospital · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
To compare efficacy and safety of Abivertinib maleate alone versus standard first-line EGFR-TKIs for the treatment of patients with advanced non-small cell lung cancer with sensitive EGFR mutation
Timeline
- Start
- 2019-03
- Primary completion
- 2022-03
- Completion
- 2024-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abivertinib | Small molecule | 300 mg | Oral |
| Comparator | Gefitinib | Small molecule | 250 mg | Oral |